SCHEMBL21848618

SCHEMBL21848618

N#Cc1ccc(C2(C#N)CCN(CCCCCc3cccc4c3CN(C3CCC(=O)NC3=O)C4=O)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 13/20 0.46
▸ TNF P01375 7/20 0.45
▸ IKZF3 Q9UKT9 9/20 0.45
▸ DDB1 Q16531 4/20 0.45
▸ IL1B P01584 4/20 0.45
▸ IKZF1 Q13422 3/20 0.45
▸ BRD4 O60885 1/20 0.45
▸ ADRA1D P25100 1/20 0.44
▸ ADRA1A P35348 1/20 0.44
▸ ADRA1B P35368 1/20 0.44
▸ CSNK1A1 P48729 1/20 0.44
▸ ALK Q9UM73 1/20 0.41
▸ IKZF2 Q9UKS7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21848789 0.93 CRBN (0.46) CRBNTNFIKZF3DDB1IL1B
SCHEMBL21848801 0.93 CRBN (0.46) CRBNTNFIKZF3DDB1IL1B
SCHEMBL23740100 0.93 CRBN (0.50) CRBNTNFIKZF3DDB1IL1B
SCHEMBL21848800 0.92 CRBN (0.47) CRBNTNFIKZF3DDB1IL1B
SCHEMBL21848608 0.91 CRBN (0.48) CRBNTNFIKZF3DDB1IL1B
SCHEMBL21848811 0.91 CRBN (0.46) CRBNTNFIKZF3DDB1IL1B
SCHEMBL21848815 0.90 CRBN (0.45) CRBNTNFIKZF3DDB1IL1B
SCHEMBL21848607 0.90 TNF (0.51) CRBNTNFIKZF3DDB1IL1B
SCHEMBL21848634 0.90 CRBN (0.46) CRBNTNFIKZF3DDB1IL1B
SCHEMBL21848793 0.90 CRBN (0.46) CRBNTNFIKZF3DDB1IL1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459921-B2 Isoindoline compound, preparation method, pharmaceutical composition and use thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2025-11-04 — — US disclosed
CN-114085212-A Isoindoline compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-02-25 — — CN disclosed
US-20220041576-A1 ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2022-02-10 — — US disclosed
CN-110963994-B Isoindoline compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-02-08 — — CN disclosed
EP-3862348-A1 ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2021-08-11 — — EP disclosed
EP-3862348-A1 ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2021-08-11 — — EP disclosed
CN-110963994-A Isoindoline compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2020-04-07 — — CN disclosed
WO-2020064002-A1 ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF 中国科学院上海药物研究所 2020-04-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459921-B2 Isoindoline compound, preparation method, pharmaceutical composition and use thereof CUL4B, CUL4A, UBQLN1 CRBN 23/4885TNF 2753/4885IKZF3 219/4885
US-20220041576-A1 ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF CUL4B, CUL4A, UBQLN1 CRBN 23/4885TNF 2753/4885IKZF3 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback